Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Serimmune Inc. is prosecuting a portfolio in the Biotechnology & Pharmaceuticals technology area. There is 1 pending office action currently active. This single matter represents the current focus of the company's patent activities.
The portfolio's prosecution involves 1 distinct examiner and 1 distinct art unit. This suggests that the technical scope of the filings is specialized and remains within a single administrative group at the USPTO. For the practitioner, this concentration eliminates the need to coordinate between different art units or manage multiple examiner styles.
ZOU, NIANXIANG is the busiest examiner for this portfolio, managing 1 busiest examiner pending office action. Because there is 1 pending office action in total, this examiner has sole oversight of the current active pipeline. The practitioner's strategy should be informed by the specific tendencies of this one official.
With 1 distinct examiner and 1 distinct art unit, the prosecution process is highly centralized. The practitioner can manage the 1 pending office action with a clear understanding of the single examiner's expectations. This focused approach allows for a more efficient prosecution of the company's biotechnology and pharmaceutical innovations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZOU, NIANXIANG | 1 | 64.1% | +24.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18145772 | SARS-COV-2 SERUM ANTIBODY PROFILING | ZOU, NIANXIANG | 162d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18145772 | SARS-COV-2 SERUM ANTIBODY PROFILING | ZOU, NIANXIANG | 162d overdue |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18145772 | SARS-COV-2 SERUM ANTIBODY PROFILING | ZOU, NIANXIANG | 1671 | §102§103§112 | Non-Final OA | 162d overdue | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial